BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24800858)

  • 1. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
    J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
    Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK; Haynes C; Besharat A; Green JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study.
    Degenhardt L; Bruno R; Ali R; Lintzeris N; Farrell M; Larance B
    Drug Alcohol Depend; 2015 Jun; 151():56-67. PubMed ID: 25910850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
    Sessler NE; Downing JM; Kale H; Chilcoat HD; Baumgartner TF; Coplan PM
    Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1238-46. PubMed ID: 24916486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
    Cheng HG; Coplan PM
    Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
    Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
    Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
    Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
    Hwang CS; Chang HY; Alexander GC
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internet-based survey of nonmedical prescription opioid use in the United States.
    Katz N; Fernandez K; Chang A; Benoit C; Butler SF
    Clin J Pain; 2008; 24(6):528-35. PubMed ID: 18574362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
    Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse among individuals assessed for substance abuse treatment with the Addiction Severity Index-Multimedia Version (ASI-MV).
    Rodriguez RD; Dailey Govoni T; Rajagopal V; Green JL
    Curr Med Res Opin; 2023 Apr; 39(4):579-587. PubMed ID: 36762423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Motivations for Using Buprenorphine Products Differ From Using Opioid Analgesics: Evidence from an Observational Study of Internet Discussions Among Recreational Users.
    Butler SF; Oyedele NK; Dailey Govoni T; Green JL
    JMIR Public Health Surveill; 2020 Mar; 6(1):e16038. PubMed ID: 32209533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing abuse potential of new analgesic medications following market release: an evaluation of Internet discussion of tapentadol abuse.
    McNaughton EC; Black RA; Weber SE; Butler SF
    Pain Med; 2015 Jan; 16(1):131-40. PubMed ID: 25244069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.